Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington Disease
a study on Huntington's Disease
Huntington Disease Gene therapy AAV (adeno-associated virus) serotype 5 AAV (adeno-associated virus) serotype 5 Viral vector miHTT muHTT Huntington Disease (HD) intra-striatal rAAV5-miHTT
Lead Scientist at UC Health
- Michael Geschwind, MD, Ph.D. (ucsf)
Dr. Geschwind received his M.D.and Ph.D. in neuroscience through the National Institutes of Health (NIH)-sponsored Medical Scientist Training Program (MSTP) at the Albert Einstein College of Medicine in New York.
- accepting new patients
- Start Date
- Completion Date
- UniQure Biopharma B.V.
- Phase 1/2
- Study Type
- Last Updated